| http://www.w3.org/ns/prov#value | - The global Phase 3 (PREVAIL) trial was a randomized, multicenter, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy and safety of Qudexy??? XR as adjunctive therapy in patients with refractory POS. The study enrolled 249 adult patients worldwide at 66 centers.
|
